PI3K inhibitors in thrombosis and cardiovascular disease

被引:65
|
作者
Durrant, Tom N. [1 ]
Hers, Ingeborg [2 ]
机构
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2020年 / 9卷 / 01期
关键词
Cardiovascular disease; Thrombosis; Platelets; Phosphoinositide; 3-kinase; PI3K; Phosphoinositides; Cellular signalling; II PHOSPHOINOSITIDE 3-KINASE; REGULATES PLATELET ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PI3K-GAMMA INHIBITION; P110-ALPHA ISOFORM; P110-BETA SUBUNIT; CRYSTAL-STRUCTURE; P2Y(12) RECEPTOR; DOSE-ESCALATION; CELL-MIGRATION;
D O I
10.1186/s40169-020-0261-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Biomarkers for predicting response to PI3K inhibitors
    Cantley, Lewis C.
    CANCER RESEARCH, 2011, 71
  • [42] The role of PI3kγ and PI3kδ in alloimmunity
    Uehara, Mayuko
    Jamil, Azzi
    Ohori, Shunsuke
    Solhjou, Zhabiz
    McGrath, Martina
    Banouni, Naima M.
    Evans, Catherine A.
    Dinitto, Jonathan P.
    Winkler, David G.
    Abdi, Reza
    TRANSPLANTATION, 2016, 100 (07) : S361 - S361
  • [43] Taking PI3Kδ and PI3Kγ One Step Ahead: Dual Active PI3Kδ/γ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases
    Rommel, Christian
    PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 1, 2010, 346 : 279 - 299
  • [44] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [45] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2012, 72
  • [46] Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors
    Spoerke, Jill
    Desai, Rupal
    Patel, Rajesh
    Fredrickson, Jill
    Wang, Yulei
    Levy, Gallia
    Gendreau, Steve
    Lauchle, Jennifer
    Derynck, Mika
    Raja, Rajiv
    Koeppen, Hartmut
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2013, 73 (08)
  • [47] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [48] The PI3K Pathway in Human Disease
    Fruman, David A.
    Chiu, Honyin
    Hopkins, Benjamin D.
    Bagrodia, Shubha
    Cantley, Lewis C.
    Abraham, Robert T.
    CELL, 2017, 170 (04) : 605 - 635
  • [49] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740
  • [50] Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations
    Bonelli, M.
    Cavazzoni, A.
    La Monica, S.
    Galetti, M.
    Caffarra, C.
    Cretella, D.
    Saccani, F.
    Fumarola, C.
    Alfieri, R.
    Petronini, P. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S166 - S167